Nuclear β-Catenin Exclusion
Endometriosis should not have to be managed forever.
It should be made to end.
A founder-led precision-peptide research programme created by Bogdan Dicoias to investigate whether pathological nuclear β-catenin signalling can be selectively intercepted — allowing endometriotic lesions to regress without suppressing the reproductive endocrine system.
Independent peptide research by Bogdan Dicoias
Panacea Bio Chem Research Universe
For decades, endometriosis has largely been approached through pain management, hormonal suppression and surgery. These approaches can be essential — but they do not answer the central scientific question.
Can the pathological programme that allows an endometriotic lesion to survive, invade and return be interrupted at its molecular source?
NBetaX™ was created around that question. Its ambition is not another temporary reduction in symptoms. Its ambition is a short-course, non-hormonal precision treatment capable of driving lesion regression, extinguishing the inflammatory environment that sustains disease, preserving healthy reproductive biology and reducing the likelihood of recurrence.
This is the cure question. NBetaX™ exists to pursue it.
β-catenin performs several legitimate functions within healthy tissue. At the cell membrane, it contributes to cell–cell adhesion through cadherin-associated complexes. Its behaviour changes when pathological signalling causes β-catenin to accumulate in the cytoplasm and enter the nucleus.
Inside the nucleus, β-catenin can participate in transcriptional programmes associated with:
Do not indiscriminately eliminate β-catenin. Intervene at the pathological nuclear event.
NBetaX™ investigates peptides engineered to restrict disease-associated β-catenin nuclear activity while preserving essential physiological functions elsewhere in the cell.
The thesis in the primary literature. The Wnt/β-catenin pathway was proposed as a therapeutic target in endometriosis in 2014, and the evidence since spans reviews, human-cell studies and animal models:
For an NBetaX™ candidate to succeed, it must be designed to achieve four connected objectives. This is not conventional symptom suppression — it is precision control of a pathological intracellular state.
Reach or become preferentially active within pathological endometriosis tissue.
Cross the cellular barrier and access the intracellular compartment in which β-catenin signalling is operating.
Bind a selected molecular interface involved in β-catenin trafficking or transcriptional activity.
Interrupt lesion-supporting signalling strongly enough to permit regression, immune clearance and durable remission.
The modality in the primary literature. Peptides and peptidomimetics that bind β-catenin protein-protein interfaces directly — the class of molecule capabilities 02–04 require — have been published since 2017, in chemical-biology and oncology contexts rather than in endometriosis:
The first endometriosis-focused NBetaX candidate — a novel, independently engineered peptide, synthesized by Bogdan Dicoias on the SYNTHESERACT™ CF-SPPS machine, intended to investigate selective interference with pathological β-catenin nuclear signalling in endometriosis-associated cells.
NBetaX™ is the platform, the biological thesis and the wider therapeutic class. N-BX™ is the translational identity and candidate family. N-BX01™ is the lead nuclear β-catenin exclusion peptide for endometriosis.
Enter the N-BX01 programme
Bogdan Dicoias did not begin by asking how another endometriosis medicine could be produced. He began by asking why a disease affecting the lives, fertility and autonomy of millions remains something patients are expected to suppress indefinitely.
His work across the Panacea Bio Chem research universe has centred on peptide engineering, synthesis technology, formulation behaviour, preservation, controlled delivery and the machinery required to transform molecular concepts into physical candidates.
NBetaX™ brings those disciplines together around one objective: to design a peptide capable of stopping endometriosis at an intracellular control point rather than temporarily silencing the body around it. The programme is founder-directed, mechanism-led and built to progress from molecular design through synthesis, analytical characterisation, biological testing and clinical translation.
NBetaX™ is structured around the requirements of eventual clinical translation. Each stage illuminates as a real milestone is reached; the stages ahead remain outlined.
Identification of β-catenin-associated molecular interfaces relevant to pathological nuclear activity, then design of peptide variants for affinity, selectivity, stability, cellular entry and lesion-directed activity.
The N-BX candidate series is synthesized by Bogdan Dicoias on SYNTHESERACT™ — his own CF-SPPS continuous-flow solid-phase peptide synthesis platform — then characterised for identity, mass, purity, impurity mapping, aggregation, solubility and stability.
Cell entry, intracellular localisation, target engagement, β-catenin redistribution and downstream transcription — then lesion regression, inflammation, fibrosis, reproductive-cycle preservation and recurrence after withdrawal.
Within the NBetaX™ programme, a potential cure would not simply mean that pain improved during treatment. It would require a far higher standard. The ambition is not to use the word lightly — the ambition is to make the word measurable.
A disease-directed treatment could separate endometriosis therapy from chronic endocrine suppression.
Successful lesion resolution could reduce dependence on repeated excision procedures.
A non-hormonal mechanism could potentially preserve ovulation, ovarian function and future reproductive choices.
The ultimate goal is not lifelong medication. It is a defined intervention followed by durable remission.
The NBetaX™ Research Journal records the evolution of the programme through dated scientific milestones. Science should leave a chronology. This is ours.
The literature around endometriosis, Wnt/β-catenin signalling and non-hormonal peptide therapeutics moves weekly. Recent entries below, refreshed from PubMed.
Recent developments in the field — refreshed 2026-09-07 by Panacea Bio Chem.
Endometriosis is not a normal consequence of being born female. It is a biological disease.
Biological diseases have mechanisms. Mechanisms can be interrogated. Targets can be reached. And one day, the correct molecule may make the disease stop.
NBetaX™ is being built for that day.
What are peptides?
Peptides are molecules made from two or more amino-acid residues joined by peptide bonds. In everyday biomedical use, the term usually refers to amino-acid chains smaller than proteins, although the exact size boundary is not absolute. Their biological activity depends on sequence, structure and chemical modifications rather than on the word “peptide” alone. — sources: IUPAC Gold Book — peptides, NCBI MeSH — Peptides, NCBI/NCI — peptide definition
How do peptides work in the body?
Many endogenous peptides act as signalling molecules. They bind to receptors, enzymes, membranes or other molecular partners and change cellular behaviour such as hormone release, metabolism, inflammation, growth or tissue signalling. Different peptides can have completely different targets, so “peptides” should never be treated as one biological effect. — sources: Nature Reviews Drug Discovery — Trends in peptide drug discovery, AAMC — 10 questions to ask your doctor about peptides, Tufts Medicine — Peptides explained
What is the difference between peptides and proteins?
Both peptides and proteins are built from amino acids. Peptides are generally shorter chains, while proteins are usually longer and more likely to adopt complex three-dimensional structures. The boundary is conventional rather than absolute, so sequence length alone does not fully determine whether a molecule is called a peptide or protein. — sources: NCBI MeSH — Peptides, Nature Reviews Drug Discovery — Trends in peptide drug discovery
Are peptides steroids?
No. Peptides are amino-acid chains linked by peptide bonds, whereas steroids are molecules built around a characteristic four-ring carbon framework. Some peptides and some steroids can influence overlapping physiological systems, which is why they are sometimes discussed together, but chemically they are very different classes of molecule. — sources: IUPAC Gold Book — peptides, Harvard Health — Peptides: benefits and safety concerns
Are peptides hormones?
Some peptides are hormones, but many are not. Insulin, glucagon, oxytocin and many other signalling molecules are peptide hormones, while other peptides function as neurotransmitters, growth factors, antimicrobial molecules, research probes or synthetic drug candidates. “Peptide” describes chemistry; “hormone” describes biological function. — sources: Nature Reviews Drug Discovery — Trends in peptide drug discovery, AAMC — 10 questions to ask your doctor about peptides
Are peptides the same as amino acids?
No. Amino acids are the individual molecular building blocks. Peptides are formed when two or more amino-acid residues are joined, typically through peptide bonds. A peptide’s properties emerge from the sequence, length, charge, conformation and modifications of its component residues. — sources: IUPAC Gold Book — peptides, NCBI MeSH — Peptides
What is a peptide bond?
A peptide bond is the amide linkage that connects the carbonyl carbon of one amino-acid residue to the nitrogen of another. Repeating peptide bonds create the backbone of peptide chains. The sequence and side chains attached to that backbone determine much of a peptide’s chemistry and biological recognition. — sources: IUPAC Gold Book — peptides
How many amino acids are in a peptide?
There is no universally rigid cutoff. Peptides contain at least two amino-acid residues; terms such as oligopeptide, polypeptide and protein overlap, and different fields use somewhat different length conventions. It is better to state the actual sequence length than rely on a single arbitrary peptide/protein boundary. — sources: NCBI MeSH — Peptides, IUPAC Gold Book — peptides
Are peptides natural or synthetic?
Both. Living organisms produce many peptides naturally, while laboratories can synthesize identical sequences, analogues or entirely designed sequences. Synthetic chemistry also allows non-natural amino acids, cyclization, lipidation and other modifications that can alter stability, potency or pharmacokinetics. — sources: Nature Reviews Drug Discovery — Trends in peptide drug discovery, PubMed — Fmoc Solid-Phase Peptide Synthesis
Why can two peptides have completely different effects?
A change in amino-acid sequence can alter charge, shape, receptor affinity, stability and cellular distribution. Even closely related peptides can therefore engage different targets or behave differently in solution and in vivo. Sequence and structure, not the generic label “peptide,” determine function. — sources: Nature Reviews Drug Discovery — Trends in peptide drug discovery, PubMed — Factors affecting peptide aggregation
The NBetaX ladder: NBetaX (platform and therapeutic class) → N-BX (translational candidate family) → N-BX01 (lead candidate). The canonical name decomposes as Nuclear βeta-catenin eXclusion.
The target protein is indexed as beta-catenin, β-catenin, beta catenin, CTNNB1 (its gene) and catenin beta-1.
The pathway is indexed under Wnt: Wnt signalling (UK) / Wnt signaling (US), the canonical Wnt pathway, and the Wnt/β-catenin pathway, with its nuclear effectors TCF/LEF and TCF4, the co-activator BCL9, and the destruction-complex proteins Axin, APC and GSK3β. The nuclear step is described as nuclear translocation, nuclear localisation or nucleocytoplasmic distribution. PubMed indexes 69 records for endometriosis AND "Wnt signaling" (count verified 2026-09-08) — the literature of this programme lives under the Wnt vocabulary even though the programme's own name does not contain it.
The disease terms: endometriosis, endometriotic lesion, ectopic endometrium, eutopic endometrium, endometrioma and deep infiltrating endometriosis. Adenomyosis is an adjacent condition, not the same one.
The category terms: non-hormonal endometriosis treatment, disease-modifying endometriosis therapy, precision peptide, lesion regression, protein-protein interaction inhibitor, peptidomimetic, cell-penetrating peptide and stapled peptide.
The Panacea Technology Universe
Proprietary Panacea Bio Chem Ltd technologies, invented by Bogdan Dicoias — what each one does, and why it leads its class.
Lyoprester®The only dual-chamber cartridge that is autoreconstitution-enabled, vacuum-sealed and argon-fillback.lyoprester.com ↗
P-EARLs™Panacea-Engineered Aseptic Reconstitution Liquid(s) — each tuned to the peptide it wakes.p-earls.com ↗
Peptourbillon™The layered peptide formulation architecture — single- or multi-layer, never a blend.peptourbillon.com ↗
RF Tunnel™The RF-formed central channel through the cake.rftunnel.com ↗
TgShift™Raises the cake’s glass-transition temperature with RF — instead of chilling below it.tgshift.com ↗
Cryolapse™Cryogenic pressure collapse under S3Pulse™ control — vapour redistributed through the whole cake, not its surface, impeding crust formation.cryolapse.com ↗
LyoLevit™The cake levitates and spins in high orbit — driven by ultrasound and RF.lyolevit.com ↗
Lyochrysalis™The integrated chamber housing the whole drying stack.lyochrysalis.com ↗
S3Pulse™The control brain for every piece of Panacea hardware.s3pulse.com ↗
Liquiprester™The single-liquid cartridge engineered so multiple peptide APIs coexist in one shared vehicle.liquiprester.com ↗
Syntheseract™Continuous-flow peptide synthesis in a special, very fast and economical way.syntheseract.com ↗
CFSPPS™Continuous-flow solid-phase peptide synthesis, written as its own category.cfspps.com ↗
OxyDeplete™Degassing plus no-headspace doctrine — the oxygen-starved seal.oxydeplete.com ↗
ArgonLock™The final inert-atmosphere lock under argon.argonlock.com ↗
RedoxVault™Separation, not merely suppression — redox isolation in lipid micro-reservoirs.redoxvault.com ↗
PleniDose™The shared filling gantry — one machine filling both the dual-chamber Lyoprester and the liquid Liquiprester.plenidose.com ↗
IncreSure™The dose-metrology layer — verified API per pen increment.incresure.com ↗
ElimiVoid™Front-void elimination without touching the metered dose.elimivoid.com ↗
Cryoviscous™The characterised cold, high-viscosity, low-mobility conditioning state.cryoviscous.com ↗
Vana Machine™Vacuum Assisted Needle Accessory — vacuum conditioning and plunger-locking for the cartridge.
EZnject™The disposable auto-injector pen built around the Lyoprester.panaceaeznject.com ↗
Dicoias ΨThe computed-chemistry advisory — every substance reduced to a vector across physical, electronic and formulation space.dcppsi.com ↗
SealoPrester™Aseptic Cartridge Closure System — Seal o’ Precision + Sterility.sealoprester.com ↗
Peptidic LiquidThe peptide formulation in solution — the active plus its buffers, cryoprotectants, lyoprotectants and scaffolders.peptidicliquid.com ↗
DiastolVAC™Biomimetic diastolic vacuum control — the pneumatic circulatory system of the machine: pumps, valves and sensors as one ensemble.diastolvac.com ↗The publications indexed in PubMed in the last 30 days for "endometriosis" AND ("beta-catenin" OR "Wnt signaling" OR "Wnt signalling") already appear in Trending above — the next most recent in the field, refreshed weekly.